



Guidance for Use of Previously Approved Lines from NIH hESC Registry in CIRM-Funded Research

On March 29, 2010 the Independent Citizens Oversight Committee (ICOC) of the California Institute for Regenerative Medicine reaffirmed its intent that stem cell lines previously approved by NIH be treated as "acceptably derived" materials for the purpose of conducting CIRM-funded research. As a result of this action, researchers may continue to utilize lines previously approved by NIH without additional review by a stem cell research oversight committee.

The ICOC reiterated that additional lines may also be used in CIRM-funded research provided that they satisfy CIRM's "acceptably derived" standard, including approval by an IRB or an IRB-like entity for international lines where necessary.